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INCLISIRAN (LEQVIO)

ABSTRACT
This article provides an abbreviated overview of the newly
Federal Drug Administration (FDA)approved novel drugs of
2021-2022 with their respective approved indication(s). The
FDA serves as the governing body that regularly evaluates and
approves medications that will eventually be introduced to the
market for routine use. These medications include both drugs
that are the same or related to previously approved products
(e.g., Extended indications of priorly approved medications) and
novel drugs. By definition, a novel drug is an innovative product
which serves to improve quality care in patient populations with
unmet or advanced medical needs to overall advance patient
care and public health. This article was employed to highlight
medications that may be seen in practice and to heighten overall
awareness of these new drugs. From January 1, 2021, through
June 13, 2022, the FDA approved 66 drugs characterized as
novel (Table 1). The four drugs highlighted in this article were
selected based on potential inpatient and outpatient utility,
disease-state prevalence, and overall innovative medicationbased treatment approaches. The four highlighted drugs are
included in Table 2.

H

epatocytes are responsible for the
removal of circulating low-density lipoprotein (LDL) from the
plasma through LDL receptor-mediated
endocytosis.1 Hepatocytes produce proprotein convertase subtilisin-kexin type 9
(PCSK9), a serine protease, which binds
to LDL-receptors. This binding results in
lysosomal degradation and ultimately a
reduction in LDL receptors and an elevation in circulating plasma LDL-C.2 Hypercholesterolemia, a chronic disease-state
marked by an elevated LDL-C, remains a
significant risk factor in the development
of cardiovascular disease. Therefore, clinically significant reductions in LDL-C can
reduce the risk of cardiovascular disease
and improve cardiovascular outcomes.2,3
nclisiran is an oligonucleotide that is
conjugated to triantennary N-acetylgalactosamine carbohydrates which
facilitates the drug’s binding to asialoglycoprotein receptors expressed on hepatocytes of the liver. Upon uptake of inclisiran into the hepatocyte, inclisiran binds to
RNA-induced silencing complex (RISC),
which is a ribonucleoprotein complex
that primarily functions in gene silencing
and regulation. Single strand RNA serves
as a template for RISC to determine appropriate messenger RNA complements.
RISC can also activate ribonuclease
(RNase) and can cleave target mRNA.2
Incorporation of inclisiran to RISC disrupts PCSK9 translation through targeted
cleavage of PCSK9 specific mRNA. This
cleavage results in the decreased hepatic
production of PCSK9 which consequently allows for increased LDL-receptor

I
Correspondence to Michael Do
at Michael.do@towerhealth.org
Disclosure Statement: The authors have no
conflicts of interest to declare.
Acknowledgements: We thank Dr. Matt Alspach, PharmD
and Regine Ghoubrial-Wiabel, PharmD for precepting and
guiding the project. We thank Dr. Adam Sigal, MD FACEP
FAAEM for providing guidance and comments on the article.
© Tower Health

Transform Med | Vol 1, No 3. September 2022 | https://doi.org/10.54299/tmed/zcno1399

72

Do et al.

Novel Drug Approvals for 2021-2022 – Year in Review

recycling and concentration thereby decreasing circulating LDL-C.3 It is recommended to administer
inclisiran in combination with maximally tolerated
statin therapy. Due to the established CV morbidity
and mortality benefits of statin therapy, inclisiran use
is reserved as an alternative augmentation therapy.
The ORION-9, -10 and -11 clinical trials examined
the use of Inclisiran as an adjunct to diet and maximal statin therapy for treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or
clinical atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of low-density lipoprotein cholesterol (LDL-C). Across all three
trials, Inclisiran use resulted in statically significant
percentage change in LDL-C from baseline to day
510 when compared to placebo, suggesting its clinical prevalence and utility in outpatient management
of ASCVD and HeFH. The ORION-10 and -11 trials
examined inclisiran-use in the setting of ASCVD and
found that inclisiran-use was correlated to a significant reduction in LDL-C when compared to placebo.
Similar results were also produced in the ORION-9
trial, which focused primarily on inclisiran verses
placebo in the setting of HeFH. The effect of inclisiran on CV morbidity and mortality has not been
determined. Common adverse reactions occurring
greater than or equal to 3% of inclisiran patients as
compared to placebo included antibody development, injection site reaction, arthralgia, urinary tract
infections, diarrhea, bronchitis, pain in extremities
and dyspnea.
The recommended dose of Inclisiran is 284mg as a
single subcutaneous injection once initially with additional doses administered at 3 months and then every 6 months thereafter. In terms of efficacy monitoring, it is recommended to monitor LFTs (fasting or
non-fasting) before initiation of treatment and then
reassess fasting lipid profile 4-12 weeks after starting
therapy and then every 3-12 months thereafter. Toxicity monitoring consists of antibody development,
injection site reaction, arthralgia, urinary tract infections, diarrhea, bronchitis, pain in the extremities and
dyspnea.4,5
VERICIGUAT (VERQUVO)
More than 6 million Americans are living with heart
failure. Over 900,000 new cases are diagnosed each
year.6 Approximately 50% of heart failure patients
have heart failure with a reduced ejection fraction of
40%.7 Heart failure with reduced ejection fraction
(HFrEF) is also known as systolic failure. The left
ventricle loses its ability to contract normally, rendering the heart unable to maintain adequate perfusion.
© Tower Health
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Vericiguat (Verquvo) is the first oral soluble guanylate cyclase (sGC) stimulator developed and
approved for the treatment of heart failure (HF).
Specifically, it is indicated to reduce the risk of cardiovascular death and heart failure hospitalization
following a hospitalization for heart failure or need
for outpatient IV diuretics in adults with symptomatic chronic HF and an ejection fraction less than
45%.8 Vericiguat is a stimulator of soluble guanylate
cyclase (sGC), an important enzyme in the nitric oxide signaling pathway. When nitric oxide binds to
the enzyme sGC, the enzyme catalyzes the synthesis of intracellular cyclic guanosine monophosphate
(cGMP), a second messenger that plays a role in the
regulation of vascular tone, cardiac contractility, and
cardiac remodeling.8 cGMP is activated independent
of nitric oxide involvement. Vericiguat also works
by sensitizing sGC to nitric oxide by stabilizing nitric oxide binding to the binding site. Ultimately,
vericiguat replenishes the cGMP in the presence of
oxidative stress and low nitric oxide.9,10 Heart failure
is associated with impaired synthesis of nitric oxide
and decreased activity of sGC, which may contribute to myocardial and vascular dysfunction. Through
the direct, independent, and synergistic stimulation
of sGC with nitric oxide, vericiguat augments levels
of intracellular cGMP, which leads to smooth muscle
relaxation and vasodilation.8
The VICTORIA trial was conducted to assess the
effect of vericiguat (Verquvo) in patients with heart
failure with reduced ejection fraction (HFrEF) who
had recently been hospitalized or had received IV
diuretic therapy. The primary endpoint of the trial
was a composite of time of first cardiovascular death
or hospitalization for heart failure. The secondary
endpoints identified were cardiovascular death and
heart failure hospitalization.9,10 The primary composite endpoint of vericiguat was superior to placebo at 33.6 events/100 patient-yr vs 37.8 events/100
patient-yr respectively. Vericiguat significantly lowered cardiovascular death and hospitalization (16.4%
vs 17.5%; CI 0.90 (0.82-0.98) and 27.4% vs 29.6%
CI 0.90 (0.81-1), respectively.9,10 To prevent a primary-outcome event with vericiguat, the number needed to treat (NNT) is 24 patients per 1 year. Though
the number needed to harm (NNH/0.9 years) for the
clinical endpoints of symptomatic hypotension and
syncope are not statistically significant, the NNH/0.9
years for anemia is 53 patients.11
Within the VICTORIA clinical trial, the most observed adverse events with vericiguat were hypotension 9.1% vs 7.9% P=0.12, syncope 4% vs 3.5%;
P=0.3, and anemia 7.6% vs 5.7%; P<0.001.9,10 With
concern for potential hypotension and syncope, con-
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Table 1.– FDA-approved medications in 2021-2022
Brand Name

Generic Name

Quviviq

Daridorexant

Cibinqo

Abrocitinib

1/14/2022 Refractory, moderate-to-severe atopic dermatitis

Kimmtrak

Tebentafusp-tebn

1/25/2022 Unresectable or metastatic uveal melanoma

Vabysmo

Faricimab-svoa

1/28/2022 Neovascular (wet) aged-related macular
degeneration and diabetic macular edema

Enjaymo

Sutimlimab-jome

Pyrukynd

Mitapivat

2/17/2022 Hemolytic anemia in pyruvate kinase deficiency

Vonjo

Pacritinib

2/28/2022 Intermediate or high-risk primary or secondary
myelofibrosis in adults with low platelets

Opdualag

Nivolumab and
Relatlimab-rmbw

3/18/2022 Unresectable or metastatic melanoma

Ztalmy

Ganaxolone

3/18/2022 Seizures in cyclin-dependent kinase-like 5 deficiency disorder

Pluvicto

Lutetium (177Lu)
vipivotide tetraxetan

3/23/2022 Prostate-specific membrane antigen-positive metastatic
castration-related prostate cancer following other therapies

Vivjoa

Oteseconazole

4/26/2022 To reduce the incidence of recurrent vulvovaginal
candidiasis (RVVC) in females with a history of
RVVC who are not of reproductive potential

Camzyos

Mavacamten

4/28/2022 To treat certain classes of obstructive
hypertrophic cardiomyopathy

Voquezna

Vonoprazan, amoxicillin,
and clarithromycin

Mounjaro

Tirzepatide

5/13/2022 To improve blood sugar control in diabetes,
in addition to diet and exercise

Vtama

Tapinarof

5/23/2022 Plaque psoriasis

Amvuttra

Vutrisiran

6/13/2022 Polyneuropathy of hereditary transthyretinmediated amyloidosis

Leqvio

Inclisiran

12/22/2021 To treat heterozygous familial hypercholesterolemia
or clinical ASCVD as add-on therapy

Tezspire

Tezepelumab-ekko

12/17/2021 To treat severe asthma as an add-on maintenance therapy

Qulipta

Atogepant

Aduhelm

Aducanumab-avwa

6/7/2021 To treat Alzheimer’s disease

Brexafemme

Ibrexafungerp

6/1/2021 To treat vulvovaginal candidiasis

Nextstellis

Drospirenone and Estetrol

Qelbree

Viloxazine

Zegalogue

Dasiglucagon

3/22/2021 To treat severe hypoglycemia

Cosela

Trilacicilib

2/12/2021 To mitigate chemotherapy-induced
myelosuppression small cell lung cancer

Evkeeza

Evinacumab-dgnb

2/11/2021 To treat homozygous familial hypercholesterolemia

Tepmetko

Tepotinib

Cabenuva

Cabotegravir
and rilpivirine

1/21/2021 To treat HIV

Verquvo

Vericiguat

1/19/2021 To mitigate the risk of CV death and
hospitalization for chronic heart failure

© Tower Health

Approval Date FDA-approved indication(s)
1/7/2022 Insomnia

2/4/2022 To decrease the need for RBC transfusion due
to hemolysis in cold agglutinin disease

5/3/2022 Helicobacter Pylori infection

9/28/2021 To prevent episodic migraines

4/15/2021 To prevent pregnancy
4/2/2021 To treat ADHD

2/3/2021 To treat non-small cell lung cancer
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Table 2.– Highlighted FDA-approved medications in 2021-2022
Generic

Trade

Dosing

Adverse Effects

Monitoring

Inclisiran

Leqvio

284mg IM x 1, again at 3 months,
and then every 6 months thereafter

Antibody development
Injection site reaction:
Arthralgia, Urinary tract
infections, Diarrhea,
Bronchitis, Pain in
extremities
Dyspnea

Lipid profile (fasting or nonfasting) before initiation of
treatment. Fasting lipid profile
should be reassessed 4-12
weeks after starting therapy
and then every 3-12 months
thereafter

Vericiguat

Verquvo

Recommended starting dose is 2.5
mg orally once daily with food
Double the dose of vericiguat
approximately every 2 weeks to
reach the target maintenance dose
of 10 mg once daily, as tolerated
by the patient

Most reported ≥5%
are hypotension and
anemia

Monitor blood pressure, heart
rate, and hemoglobin

Cabotegravir/
Rilpivirine

Cabenuva

Monthly: 600 mg cabotegravir and
900 mg rilpivirine at month 1, then
400 mg cabotegravir and 600 mg
rilpivirine monthly

Injection site
reactions: Pyrexia
Fatigue Headache
Musculoskeletal pain
Nausea

Hepatotoxicity, signs and
symptoms of hypersensitivity
and/or skin reactions, injectionrelated reactions, mood
changes

Dysgeusia, Diarrhea,
Vulvovaginal
candidiasis, Headache,
Abdominal pain,
Hypertension

Hepatotoxicity, anaphylaxis,
c.diff, QT prolongation,
Myasthenia gravis

Every 2 months: 600 mg
cabotegravir and 900 mg rilpivirine
at month 1, month 2, then every 2
months thereafter
Vonoprazan/
Amoxicillin/
Clarithromycin

Vocqquenza

TriplePak: Vonoprazan 20 mg
Q12H, amoxicillin 1000 mg Q12H,
clarithromycin 500 mg Q12H with
or without food for 14 days Dual
Pak: Vonoprazan 20 mg Q12H and
amoxicillin 1000 mg Q8H with or
without food for 15 days

comitant use of vericiguat with PDE-5 inhibitors,
soluble guanylate cyclase (sGC) inhibitors, and
long-acting nitrates are contraindicated.9,10
When initiating vericiguat, the recommended starting dose is 2.5 mg orally once daily with food. The
dose is to then be doubled every 2 weeks to reach
the target maintenance dose of 10 mg once daily, as
tolerated by the patient.8 Vericiguat has a black box
warning of embryo-fetal toxicity and is therefore
contraindicated in pregnancy.8 Women of reproductive potential must utilize effective forms of contraception during therapy and for one month after treatment discontinuation.
CABENUVA (CABOTEGRAVIR/RILPIVIRINE)
Cabenuva is an intramuscularly injected combination therapy indicated for the treatment of HIV-1 infections in adult patients and pediatric patients over
12 years old weighing more than 35 kilograms. It
contains cabotegravir, an integrase strand transfer inhibitor (INSTI) which suppresses HIV replication by
blocking integrase and preventing the incorporation
of viral DNA into host CD4 cells. The second com© Tower Health
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ponent, rilpivirine, a non-nucleotide reverse transcriptase inhibitor, suppresses HIV replication by
inhibiting reverse transcriptase which prevents HIV
from converting RNA into DNA. Cabenuva provides
a complete two-drug antiviral treatment regimen for
HIV-1 patients and can replace current antiretroviral
therapy in virally suppressed patients with no history
of treatment failure or resistance to cabotegravir or
rilpivirine.12,13,14
There are two dosing schedules available for Cabenuva: every 1 month and every 2 months. Either regimen can be preceded by a one-month oral lead-in to
assess tolerability prior to starting therapy with the
long-acting injectable formulation. The first Cabenuva injection should be administered on the same day
as the last dose of the patient’s current antiretroviral
or oral lead-in regimen. The standard monthly regimen is dosed at 600 mg cabotegravir and 900 mg rilpivirine at month 1 and 400 mg cabotegravir and 600
mg rilpivirine every 1 month thereafter. The every 2
month regimen is dosed at 600 mg cabotegravir and
900 mg rilpivirine at month 1, month 2, and every 2
months thereafter. Cabenuva is injected intramuscu-

Transform Med | Vol 1, No 3. September 2022 | https://doi.org/10.54299/tmed/zcno1399

75

Do et al.

Novel Drug Approvals for 2021-2022 – Year in Review

larly in the gluteal muscle and must be administered
in a healthcare setting. The most commonly reported
adverse reactions are injection site reactions, pyrexia, fatigue, headache, musculoskeletal pain, and nausea. Patients should be monitored for hepatotoxicity
throughout treatment.12,13,14
The ATLAS and FLAIR clinical trials evaluated the
efficacy and safety of monthly Cabenuva administration compared to daily oral antiretroviral therapy
and found Cabenuva to be non-inferior to daily oral
antiretroviral therapy with a similar rate of treatment
failure.15 The ATLAS-2M clinical trial compared
once monthly to every 2 month dosing of Cabenuva
and found every 2 month dosing to be non-inferior
to once monthly dosing with a low rate of treatment
failure and resistance in both groups.16 The ATLAS,
FLAIR, and ATLAS-2M clinical trials evaluated patient reported outcomes regarding the preference of
Cabenuva injectable therapy compared to oral regimens and most patients reported preference for the
injectable Cabenuva formulation due to the convenience of less frequent dosing.15,16 Prescribers can
consider prescribing Cabenuva to patients who will
benefit from the monthly or every 2-month dosing
schedule due to adherence issues and are stable and
virally suppressed on their current HIV treatment
regimen without resistance or treatment failure.
VONOPRAZAN, AMOXICILLIN AND
CLARITHROMYCIN (VOQUEZNA)
Vonoprazan is a novel, first-in-class potassium competitive acid blocker (PCAB). It works by inhibition
of the H+, K+ ATPase enzyme system (AKA proton
pump) on the secretory surface of the gastric parietal
cell.17 This medication has been on the market and
indicated for Japanese duodenal ulcers, reflux esophagitis, and prevention of low-dose aspirin or NSAID
induced ulcer recurrence.18
Voquezna is a triple/dual therapy pack that was recently approved May 3rd, 2022, with plans to launch
in the second half of 2022. These packs contain Vonoprazan based therapy regimens for the treatment
of Helicobacter pylori infections. The triple pack
consists of vonoprazan 20 mg tablets, amoxicillin
500 mg capsules, and clarithromycin 500 mg tablets.
The triple pack is administered as such: vonoprazan
20 mg 1 tablet, amoxicillin 500 mg 2 capsules, and
clarithromycin 1 tablet every 12 hours with or without food for 14 days. The dual pack includes vonoprazan 20 mg tablets and amoxicillin 1000 mg
tablets. The dual pack is administered as such: vonoprazon 20 mg 1 tablet every 12 hours and amoxicillin
500 mg 2 capsules every 8 hours. Contraindications
© Tower Health

to the packs include hypersensitivity reactions to any
component and concomitant use with ripilvirine. Additional warnings include (but are not limited to) QT
prolongation, increased risk for clostridium difficile,
severe cutaneous reactions.17 The most common adverse events reported Vonoprazon’s adverse effects
include but are not limited to erythema and gastrointestinal symptoms. One case of erythema multiforme that was treated with steroids was reported.
Other considerations would include concomitant use
of CYP 3A4 substrates, as it has been reported that
vonoprazon has increase 3A4 inhibition, especially
in those with hepatic dysfunction.19
Guidelines recommend eradication of H. pylori
whenever possible as it is the leading cause of peptic
ulcers, gastric adenocarcinoma, and gastric mucosa
associated lymphoid tissue lymphoma.20 However,
due to increasing clarithromycin resistance, H. pylori
susceptibility rates have dipped below 80%. H.pylori’s susceptibility rates to antibiotics is heavily influenced by gastric pH. Vonoprazan has been widely
used in East Asia with great efficacy in maintaining
gastric acid suppression, thus giving the potential
for better H. pylori eradication. A pivotal open label
phase 3 randomized control trial examined the use of
therapy vonoprazan double/triple versus the standard
treatment with lansoprazole triple therapy for resistant and non-resistant H.pylori eradication in 1046
treatment naïve adults.21 A standard triple therapy
regimen includes a PPI, clarithromycin, and amoxicillin or metronidazole.22 Both the double and triple
vonoprazon regimens were found to be statistically
superior to the PPI-based triple therapy in clarithromycin resistant strains as well as the overall study
population. Adverse events due to vonoprazon were
similar to lansoprazole.

Transform Med | Vol 1, No 3. September 2022 | https://doi.org/10.54299/tmed/zcno1399

76

Do et al.

Novel Drug Approvals for 2021-2022 – Year in Review

REFERENCES
16. J aeger H, Overton ET, Richmond G, et al. Long-acting cabotegravir and

1. G
 oldstein J, Brown M. Regulation of low-density lipoprotein receptors:
implications for pathogenesis and therapy of hypercholesterolemia and

rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M),

atherosclerosis. Circulation. 1987;76(3):504-7.

96-week results: A randomized, multicentre, open-label, phase 3b, non-

https://doi.org/10.1161/01.CIR.76.3.504

inferiority study. Lancet HIV. 2021;8(11):697-689.
https://doi.org/10.1016/S2352-3018(21)00185-5

2. K
 osmas C, Munoz Estrella A, et al. Inclisiran: a new promising agent in the

17. VOQUEZNA [package insert]. Buffalo Grove, Illinois: Phathom

management of hypercholesterolemia. Diseases. 2018;6(3):63.

Pharmaceuticals, Incorporated. Accessed August 1, 2022. Revised May 2022.

https://doi.org/10.3390/diseases6030063

18. O
 shima T, Miwa H. Potent potassium-competitive acid blockers: A new era for

3. G
 erman C, Shapiro M. small interfering RNA therapeutic inclisiran: a new
approach to targeting PCSK9. BioDrugs. 2019;34(10):1-9.

the treatment of acid-related diseases. Journal of Neurogastroenterology and

https://doi.org/10.1007/s40259-019-00399-6

Motility. 2018;24(3):334-344. https://doi.org/10.5056/jnm18029

4. L
 EQVIO [package insert]. East Hanover, New Jersey: Novartis Pharmaceuticals

19. C
 hey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical
guideline: Treatment of helicobacter pylori infection. American Journal of

Corporation. Accessed August 3, 2022. Revised December 2021.

Gastroenterology. 2017;112(2):212-239. https://doi.org/10.1038/ajg.2016.563

5. I nclisiran. Lexi-Drugs. Lexicomp Online; 2022. Accessed August 3, 2022.

20. C
 hey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW. Vonoprazan

https://online.lexi.com

triple and dual therapy for helicobacter pylori infection in the United States and

6. K
 ane SF. Heart Failure: Heart Failure With Preserved Ejection Fraction. FP
Essent. 2021;506:11-19. https://doi.org/10.1016/B978-0-323-64067-1.00033-4
7. M
 urphy SP, Ibrahim NE, Januzzi JL Jr. Heart Failure With Reduced Ejection

Europe: Randomized clinical trial. Gastroenterology. 2022;163(3):608-619.
https://doi.org/10.1053/j.gastro.2022.05.055
21. Vaira D, Zullo A, Hassan C, Fiorini G, Vakil N. Sequential therapy for

Fraction: A Review [published correction appears in JAMA. 2020 Nov

helicobacter pylori eradication: The time is now! Therapeutic Advances in

24;324(20):2107]. JAMA. 2020;324(5):488-504.

Gastroenterology. 2009;2(6):317-322.

https://doi.org/10.1001/jama.2020.10262

https://doi.org/10.1177/1756283X09343326

8.VERQUVO [package insert]. Whitehouse Station, NJ. Merck Sharp and Dohme
Corp; 2021. Published May 10, 2021. https://online.verquvo.com

22. Akazawa Y, Fukuda D, Fukuda Y. Vonoprazan-based therapy for helicobacter
pylori eradication: Experience and clinical evidence. Therapeutic Advances in
Gastroenterology. 2016;9(6):845-852.

9.Armstrong PW, Roessig L, et al. A multicenter, randomized, double-blind,

https://doi.org/10.1177/1756283X16668093

placebo-controlled trial of the efficacy and safety of the oral soluble guanylate
cyclase stimulator: the VICTORIA trial. JACC Heart Fail. 2018;6(2):96–104.
https://doi.org/10.1016/j.jchf.2017.08.013
10. Armstrong PW, Pieske B, et al. Vericiguat in Patients with Heart Failure and
Reduced Ejection Fraction. N Engl J Med. 2020;382(20):1883-1893.
https://doi.org/10.1056/NEJMoa1915928
11. Kosar, Lynette. Victoria: Vericiguat versus Placebo in Patients with Heart
Failure and Reduced EF. Rx Files Summary. Published June 2020.
12. C
 ABENUVA [package insert]. Research Triangle Park, North Carolina: ViiV
Healthcare. Accessed August 3, 2022. Revised March 2022.
13. C
 abotegravir. Lexi-Drugs. Lexicomp Online; 2022. Accessed August 3, 2022.
https://online.lexi.com
14. R
 ilpivirine. Lexi-Drugs. Lexicomp Online; 2022. Accessed August 3, 2022.
https://online.lexi.com
15. R
 izzardini G, Overton ET, Orkin C, et al. Long-acting injectable cabotegravir
+ rilpivirine for HIV maintenance therapy: Week 48 pooled analysis of phase 3
ATLAS and FLAIR trials. J Acquir Immune Defic Syndr. 2020;85(4):498-406.
https://doi.org/10.1097/QAI.0000000000002466

© Tower Health
https://scholarcommons.towerhealth.org/t-med/vol1/iss3/9
DOI: https://doi.org/10.54299/tmed/zcno1399

Transform Med | Vol 1, No 3. September 2022 | https://doi.org/10.54299/tmed/zcno1399

77

